Nasdaq GlobeNewswire

Enhesa Announces the Increase in Global Jurisdiction Coverage to 286 in 2018, and Celebrates Being Named to CIO Review's 20 Most Promising Compliance Technology Solution Providers

Del

Brussels, Belgium, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Enhesa, the leading global content provider focused on environmental, health and safety (EHS) regulatory compliance assurance support to industries worldwide, just announced the increase in global jurisdiction coverage for 2018 to reach up to 286.

Enhesa supports the Global EHS programs for many of the world's largest companies by offering a standardized, consistent suite of services enabling them to be aware of, and stay in compliance with, EHS laws wherever they operate. As a result, today, Enhesa offers off-the-shelf services in an impressive 286 jurisdictions.

New additions to the Enhesa geographic catalogue in 2018 (in English) include the following jurisdictions:

  • Argentina - Chaco
  • Argentina - Chubut
  • Azerbaijan
  • Burkina Faso
  • Canada - Northwest Territories
  • China - Guizhou
  • China - Hainan
  • China - Heilongjiang
  • Ecuador
  • German - Hanseatic City of Bremen
  • Germany - Mecklenburg - Western Pomerania
  • India Dadra -Nagar Haveli
  • India - Rajasthan
  • Macao
  • Malawi
  • Pakistan - Sindh
  • Slovenia
  • Switzerland - Solothurn
  • Switzerland - Vaud
  • Turkmenistan

Enhesa has also increased coverage by providing local language versions for the following jurisdictions:

  • Argentina - Chaco
  • Brazil - Alagoas
  • Brazil - Amazonas
  • Brazil - Maranhao
  • Brazil - Mato Grosso
  • Brazil - Parana
  • Brazil - Pernambuco
  • China - Fujian
  • China - Guizhou
  • China - Hainan
  • China - Heilongjiang
  • Guinea - National
  • Macao
  • Mali
  • Mexico - Chiapas
  • Mexico - Michoacan
  • Mexico - Quintana Roo
  • Mexico - Tlaxcala
  • Morocco
  • Paraguay
  • UAE - Abu Dhabi

Peter Hermans, Enhesa CEO further points out: "We are extremely proud of the truly global coverage we are able to offer our multinational clients. But our commitment to supporting our clients does not stop here. We will continue to partner with our current and future clients to expand our coverage as their presence around the world spreads, and provide them with the tools they need to manage EHS legal compliance at the corporate, regional, divisional and site levels."

In addition, Enhesa was selected, along with 19 other companies, to appear on CIO Review's list of "20 Most Promising Compliance Technology Solution Providers" for 2017. To help CCOs, CIOs, and CEOs find the right compliance technology provider for their enterprises, CIO Review's selection panel evaluated and shortlisted hundreds of compliance technology solution providers that are at the forefront of providing cutting-edge technology solutions.

Enhesa provides time-saving, simplified regulatory analysis translated by our in-house team of analysts - who represent approximately 45 nationalities around the world. This is why Enhesa is the leading solution to regulatory compliance forecasting and intelligence that will save you ample time and money.

To find out more about how Enhesa can help support your global EHS compliance program, please visit enhesa.com.


Company Description:

Enhesa helps global multinational companies be compliant with, and stay on top of, Environmental, Health & Safety (EHS) Regulations wherever they operate.

Enhesa's in-house team of multilingual regulatory analysts provide clear, concise and standardized content and insight on current and future EHS regulatory obligations in over 285 jurisdictions worldwide.

Enhesa's Compliance Intelligence and Regulatory Forecaster services can be provided as an automated data feed - integrated with the world's leading EHS software platforms.

Enhesa has offices in Brussels, Washington DC and Tokyo.

For more information, please visit enhesa.com or email info@enhesa.com

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ce76d13c-c729-4af3-a523-e61b4b7cc362

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1ecae2c0-6ed0-45a7-916c-f29b8c68eb53

Gloria Johnston
Enhesa
202-552-1090 ext. 203
gj@enhesa.com

Allison Gilmore
Enhesa
202-552-1090 ext. 242
agil@enhesa.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enhesa via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom